Zenas BioPharma Inc. (ZBIO)
9.95
0.04 (0.40%)
At close: Apr 24, 2025, 3:59 PM
9.98
0.30%
After-hours: Apr 24, 2025, 04:05 PM EDT
0.40% (1D)
| Bid | 9.21 |
| Market Cap | 415.82M |
| Revenue (ttm) | 5M |
| Net Income (ttm) | -156.99M |
| EPS (ttm) | -12 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | -2.24 |
| Analyst | Buy |
| Ask | 10.65 |
| Volume | 97,770 |
| Avg. Volume (20D) | 200,936 |
| Open | 9.77 |
| Previous Close | 9.91 |
| Day's Range | 9.42 - 10.13 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | -3.62 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclo...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 130
Stock Exchange NASDAQ
Ticker Symbol ZBIO
Website https://zenasbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ZBIO stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 226.63% from the latest price.
Stock Forecasts
1 day ago · accessnewswire.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIONEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / WHY: New York, N.Y., April 23, 2025.
